It's time to rethink how we do cancer research

December 5, 2017 by Eileen Parkes, The Conversation

Credit: Apple's Eyes Studio/
"A devastating failure of medical research." This was the response of one cancer survivor on hearing the news that over half of European Medical Agency-approved cancer treatments between 2009 and 2013 had no evidence of impact on quality of life or overall survival. As a cancer researcher, my goal above all is to improve patients' lives – the fact we are failing at that struck me deeply.

Understandably, some people living with cancer are angry, feel betrayed, and are questioning why we do the research we do. Have cancer researchers lost sight of what is important in patient care?

Most anti-cancer treatments are first trialled in patients where cancer has already spread beyond a curable reach (the metastatic stage). This is because we feel we can't offer an unproven when others are available. Drug then tend to move to an earlier stage – take the example of Herceptin, which was developed to combat metastatic disease, but had such a huge impact it quickly moved to the curative early treatment stage.

This approach may seem to make sense, but right now, there is a bottleneck of treatments that have only limited benefit in delaying further spread of cancer in the metastatic stage. For many of these treatments, it is unlikely they will move to the curative stage as the benefits just don't seem good enough.

Given all this, I think we need drastically to rethink our approach.

Patients first

We need to listen to what matters to patients. It is often argued that research needs space for blue sky thinking, the freedom to explore pathways and structures. But is there still room for that when we are confronted with the realities of increasing cancer rates, poor quality of life, with a 40-year-old with metastatic pancreatic cancer, for whom survival rates have not improved in the past four decades?

It is over ten years since the landmark MacMillan Listening Study published its findings from in-depth consultations with groups of cancer patients and carers about their experiences. At that time, as now, the highest priority for patients was learning to live well with cancer. New treatments lagged significantly behind, coming in at number seven in patient's priorities for cancer research. Yet fundraising campaigns still often focus on "finding a cure". The emotional grab of a potential new anti-cancer treatment is seized on by reporters whereas the subtler improvements in quality of life are not. This means that funding for cancer research is skewed towards finding new treatments.

We know early detection of cancer is key to improving survival ─ research in this area is not easy and doesn't move quickly. Only this year has exclusive funding from Cancer Research UK been set aside for early detection. But we need to encourage more research in this area.

Another area of chronic underfunding is biomarker research – many currently available treatments don't benefit everyone, but we don't know how to select which individuals they do benefit. Making our existing treatments better rather than continuing to chase new treatments is often neglected.

We have seen some improvements in this area in recent years, particularly in the inclusion of patients and carers in developing . In my experience, these are motivated, caring individuals who are, more often than not, supportive of the research we do. But researchers need to be wary that we do not simply invite those whose voices we wish to hear – we must also include those who dissent with our views and challenge our research.

Clinical trials

Clinical trials tend to be designed around what we as researchers want to know, not always what patients need. I remember an impassioned plea for improved innovative trials from a woman who had lost her husband to melanoma. Even though they didn't end up receiving the standard chemotherapy treatment (the control arm), her fear of her husband being selected for standard chemotherapy was so overwhelming it was now all she could remember. Can we focus our energy on making our trials better, switch up the design?

And of course, the trials are often funded by pharmaceutical companies, who want to show their drug in the best light. Today, many of our patients are too old for clinical trials, with the result that trials don't necessarily reflect the real world of clinical treatment. In addition, several pharmaceutical companies can chase the same target, each hoping theirs is "the best". This can saturate the market with "me too" drugs and stifle real innovation. The pharmaceutical industry has an important role to play, and they often play it well, of driving new treatments forward. But their need to keep an eye on the bottom line can be a distraction from the patient-centred research we need.

So what are some ways forward? We need a shift in research, away from a drug-focused approach to a more patient-focused approach, enshrining quality of life as a key outcome in , ensuring we don't accept inferior measurements of clinical benefit to approve a treatment. Most importantly, we need to value and carers as key partners in the progression of research.

By turning to those experiencing treatment for the next big research questions and listening carefully to their answers, we can ensure those funding and performing don't get lost in a science maze, but have a clear view of the patient with every experiment.

Explore further: Some cancer drugs approved in Europe might not have sufficient evidence of survival benefits, says study

Related Stories

Some cancer drugs approved in Europe might not have sufficient evidence of survival benefits, says study

October 6, 2017
Most cancer drugs approved in Europe from 2009-2013 weren't backed by sufficient scientific evidence that they work, according to a new study.

Cancer patients diagnosed early are more likely to avoid chemotherapy

October 26, 2017
Cancer patients are around five times more likely to have surgery to remove their tumour, and less likely to have chemotherapy, if they are diagnosed at the earliest stage compared to the latest stage, according to new figures.

Metastatic breast cancer: Bevacizumab slows progression, but has no impact on survival

July 10, 2012
The cancer drug bevacizumab (Avastin) offers only a modest benefit in delaying disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed ...

Study compares cancer drug cost, benefit

June 6, 2017
Queen's University researcher Christopher Booth reveals the price of new cancer therapies is not associated with treatment effectiveness.

New era in precision medicine for pancreatic cancer

March 23, 2017
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research ...

Effect of treatment trials on survival of patients with cancer in US population

June 6, 2017
Joseph M. Unger, Ph.D., M.S., of the SWOG Statistical Center and the Fred Hutchinson Cancer Research Center, Seattle, Wash., and coauthors examined how the National Cancer Institute-sponsored network of cooperative cancer ...

Recommended for you

Why some cancers affect only young women

October 19, 2018
Among several forms of pancreatic cancer, one of them specifically affects women, often young. How is this possible, even though the pancreas is an organ with little exposure to sex hormones? This pancreatic cancer, known ...

Scientists to improve cancer treatment effectiveness

October 19, 2018
Together with researchers from the University of Nantes and the University of Reims Champagne-Ardenne in France, experts from the National Research Nuclear University MEPhI have recently developed a quantum dot-based microarray ...

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

Loss of protein p53 helps cancer cells multiply in 'unfavourable' conditions

October 17, 2018
Researchers have discovered a novel consequence of loss of the tumour protein p53 that promotes cancer development, according to new findings in eLife.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.